New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput
PLEASANTON, Calif., May 29, 2024 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation, and industry-leading speed and throughput.
“Seeing the Xenium Prime 5K data reminded me of the excitement I experienced when I saw single cell RNA-seq data for the first time,” said Dr. Kevin Wei, M.D., Ph.D., Assistant Professor of Medicine at Harvard Medical School. “Now, we can identify relevant molecular pathways in human diseases and explore new biological hypotheses, all from one glass slide.”
The high-plex Xenium Prime 5K assay enables a new level of exploration for pathways, biomarkers, ligand-receptor pairings and cell-cell interactions. Key features include:
Highest plex Xenium panel for comprehensive profiling of cell types and states and cell signaling pathways across multiple tissue and disease types.
Excellent data quality to unlock mechanisms of disease, therapeutics and cell behavior. The Xenium Prime 5K assay is optimized for performance and paired with 10x Genomics’ advanced multimodal cell segmentation, enabling high sensitivity, specificity and spatial fidelity.
Rapid turnaround time with easy, tissue-agnostic workflows. 10x Genomics’ industry-leading throughput enables researchers to analyze up to 472 mm² of tissue in six days or less.
Easily customizable with up to 100 additional genes to capture customers’ specific research needs.
Rigorously designed and developed using single cell RNA-seq data from dozens of different organs and tissues, gene expression profiles from hundreds of cell types and a screen of more than 750,000 peer-reviewed publications to pinpoint highly cited biomarkers.
“We successfully launched Xenium with a broad menu of curated and highly customizable gene panels so customers could target specific biology important for their research,” said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. “With the launch of our 5K gene panel, researchers can now also use Xenium for spatial exploration, enabling more biology and more breakthroughs. This assay is yet another example of how we put our innovation engine to work for our customers and build best-in-class products that deliver best-in-class results.”
The Xenium Prime 5K assay, optimized for human and mouse species, is now available for preorder and is expected to ship next month.
About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the “safe harbor” provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s (“10x Genomics”) product launches, performance, configuration, capabilities, adoption and pipeline. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics’ financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the “SEC”) from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics’ views as of any date subsequent to the date of this press release.
Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
ContactsInvestors: [email protected]Media: [email protected]
SOURCE 10x Genomics, Inc
